Intravenous Ferric Carboxymaltose in Ischemic Versus Non-Ischemic Heart Failure and Iron Deficiency: Insights From FAIR-HF2.


Por: Khan MS, Butler J, Karakas M, Placzek M, Hasenfuß G, Talha KM, Bayes-Genis A, Coats AJ, Böhm M, Rosano G, Savarese G, Anker MS, Ponikowski P, Friede T and Anker SD

Publicada: 1 ago 2026 Ahead of Print: 28 sep 2025
Resumen:
BACKGROUND: Previous studies have suggested that patients with ischemic etiology of heart failure (HF) and iron deficiency may derive greater benefits with intravenous ferric carboxymaltose (FCM). We aim to assess the effects of FCM versus placebo in patients with ischemic versus non-ischemic etiology of HF. METHODS AND RESULTS: The FAIR-HF2 trial included 1105 patients with HF, with a left-ventricular ejection fraction =45%, and concomitant iron deficiency. Patients were randomized 1:1 to either intravenous FCM or placebo. Ischemic etiology was defined as investigator reported or prior coronary revascularization or myocardial infarction. The primary endpoints were time-to-first event of cardiovascular death or HF hospitalization, total HF hospitalizations, and time-to-first event of cardiovascular death or HF hospitalization in patients with transferrin saturation <20% at baseline. Of 1105 patients, 858 (78%) had ischemic etiology of HF. These were more frequently older, men and had more co-morbidities. For the first primary endpoint, FCM was associated with a hazard ratio (HR) of 0.85 (95%CI: 0.66-1.10, p=0.23) for ischemic HF and 0.61 (95% CI: 0.39-0.98, p=0.038) for non-ischemic HF (P-interaction=0.26). The HR for the second primary endpoint was 0.87 (95% CI: 0.63-1.21, p=0.41) for ischemic HF and 0.57 (95% CI: 0.35-0.94, p=0.028) for non-ischemic HF (P-interaction=0.17), while HR for the third primary endpoint was 0.84 (95% CI: 0.62-1.14, p=0.27) for ischemic HF and 0.63 (95% CI: 0.37-1.07, p=0.087) for non-ischemic HF (P-interaction=0.35). CONCLUSIONS: Effect of intravenous iron supplementation is likely similar in patients with ischemic or non-ischemic etiology of HF, just like other HF guideline-directed medical therapies.

Filiaciones:
Khan MS:
 Baylor Scott and White Research Institute, Baylor Scott and White Health, Dallas, TX, USA

 Baylor Scott and White Health -The Heart Hospital, Plano, TX, USA

 Department of Medicine, Baylor College of Medicine, Temple, TX, USA

Butler J:
 Baylor Scott and White Research Institute, Baylor Scott and White Health, Dallas, TX, USA

 Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA

Karakas M:
 Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

 German Centre for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Hamburg, Germany

Placzek M:
 Department of Medical Statistics, University Medical Center Göttingen, German Centre for Cardiovascular Research (DZHK), partner site Lower Saxony, Göttingen, Germany

Hasenfuß G:
 Clinic for Cardiology and Pneumology, University Medical Center Göttingen, German Centre for Cardiovascular Research (DZHK), partner site Lower Saxony, Göttingen, Germany

Talha KM:
 Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA

:
 Heart Failure Clinic and Cardiology Department, Hospital Germans Trias i Pujol, Badalona, CIBERCV, Spain

 Department of Medicine, Universitat Autònoma de Barcelona (UAB), Carretera del Canyet s/n, 08916, Barcelona, Spain

Coats AJ:
 Heart Research Institute, Sydney, New South Wales, Australia

Böhm M:
 HOMICAREM (HOMburg Institute for CArdioREnalMetabolic Medicine), Saarland University and Universitatsklinikum des Saarlandes, Klinik für Kardiologie, Angiologie und Internistische Intensivmedizin, Homburg/Saar, Germany

Rosano G:
 Department of Human Sciences and Promotion of Quality of Life, San Raffaele Open University of Rome, Rome, Italy

 Cardiology, San Raffaele Hospital, Cassino, Italy

Savarese G:
 Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

Anker MS:
 Charité -University Medicine Berlin corporate member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany

 German Centre for Cardiovascular Research partner site Berlin and Berlin Institute of Health Center for Regenerative Therapies, Berlin, Germany

 Department of Cardiology, Angiology and Intensive Care Medicine CBF, German Heart Center Charité, Berlin, Germany

 School of Cardiovascular and Metabolic Health, University of Glasgow, United Kingdom

Ponikowski P:
 Institute of Heart Diseases, Wroclaw Medical University, Ul. Borowska 213, 50-556, Wroclaw, Poland

 Clinical Department of Cardiology, Jan Mikulicz Radecki University Hospital in Wroclaw, Wroclaw, Poland

Friede T:
 Department of Medical Statistics, University Medical Center Göttingen, German Centre for Cardiovascular Research (DZHK), partner site Lower Saxony, Göttingen, Germany

Anker SD:
 German Centre for Cardiovascular Research partner site Berlin and Berlin Institute of Health Center for Regenerative Therapies, Berlin, Germany

 Department of Cardiology, Angiology and Intensive Care Medicine CBF, German Heart Center Charité, Berlin, Germany

 Department of Cardiology, Campus Virchow Clinic of German Heart Center Charité, Charité - University Medicine Berlin, Berlin, Germany
ISSN: 10719164





Journal of Cardiac Failure
Editorial
Churchill Livingstone, CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 32 Número: 8
Páginas: 1308-1319
WOS Id: 001849041200001
ID de PubMed: 41027507
imagen Green Submitted

MÉTRICAS